MHRA Scotland: New Commercial Research Delivery Centres Accelerate Trials

• Scotland has established four MHRA Commercial Research Delivery Centres (CRDCs), funded by the VPAG Investment Programme, as part of a 35-centre UK network.
• These CRDCs aim to fast-track clinical trials, improve patient access to innovative therapies, and drive economic growth, contributing to Scotland clinical trials acceleration.
• A hub-and-spoke model, including Practice Embedded Research Units (PERUs) and the Scottish Decentralised Clinical Trials (SCOT-DCT) initiative, is expanding research access to rural and underserved communities.
• Scotland has seen a 21% increase in clinical trial participation and secured multiple European and global firsts for patient recruitment.
• Early engagement with the MHRA is emphasized to support evidence generation and accelerate product progression from research to patient access within the life sciences ecosystem Scotland MHRA.

Early engagement between researchers, innovators, health systems, and the MHRA is actively encouraged to support evidence generation and facilitate the progression of safe and effective products from research stages to patient access.

Scotland is significantly enhancing its role within the broader UK life sciences ecosystem through the establishment of new research infrastructure, particularly the MHRA Scotland Commercial Research Delivery Centres (CRDCs). These centres represent a substantial public-private investment, strategically designed to future-proof the UK's healthcare landscape and facilitate the translation of scientific discoveries into practical medical treatments. The initiative aims to bolster Scotland's inherent strengths in clinical research, medicines development, and collaborative partnerships spanning the NHS, academia, and industry.

Funded through the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) Investment Programme, Scotland has successfully launched four CRDCs. These Scottish centres are integral components of a wider national network comprising 35 CRDCs across the UK, all working collectively to solidify the UK's standing as a global leader in commercial clinical research. The primary objectives of these CRDCs include expediting clinical trials, improving patient access to innovative therapies, and stimulating economic growth within the sector.

To ensure equitable access to research opportunities, a significant effort is underway to implement a comprehensive hub-and-spoke model. Each CRDC is partnered with a Scottish Medical School, enabling them to extend their reach through smaller satellite sites. This expansion includes integrating research into GP practices via Practice Embedded Research Units (PERUs) and directly into patients' homes through the Scottish Decentralised Clinical Trials (SCOT-DCT) initiative. These combined approaches are specifically designed to improve access to vital research for communities in rural and underserved areas across Scotland.

The strategic investments in Scotland's commercial research infrastructure are already yielding tangible benefits, demonstrating a clear acceleration in Scotland clinical trials acceleration. There has been a notable increase in the number of commercial studies being conducted across Scotland, alongside a significant rise in patient participation, which saw a 21% increase compared to the previous year. Furthermore, Scottish sites have achieved remarkable success in patient recruitment, securing five European and one global firsts.

Beyond mere statistics, these advancements are fundamentally about providing patients with access to novel medicines that are not yet approved or funded for standard NHS use. This commitment ensures that opportunities for cutting-edge treatments are made available more equitably across the country. The NHS, while a crucial engine for clinical research delivery, cannot achieve these goals in isolation, underscoring the necessity of uniting the strengths of the NHS, academia, and industry.

A prime example of this collaborative spirit is the Scotland Renal AstraZeneca (SRAZ) Programme, launched in 2024. This initiative is specifically designed to accelerate clinical research and develop targeted medicines for chronic kidney disease (CKD). Through a collaborative effort with the Universities of Glasgow and Dundee, the programme is building essential infrastructure, enhancing expertise, and widening opportunities for patients to participate in studies. Given that one in ten people in Scotland are affected by CKD, the development of new treatments to slow disease progression and reduce the need for dialysis or transplantation is critically important.

The evolution of Scotland's life sciences ecosystem MHRA highlights the critical role of regulation in this journey. Early engagement between researchers, innovators, health systems, and the MHRA is actively encouraged to support evidence generation and facilitate the progression of safe and effective products from research stages to patient access. This proactive regulatory approach is a cornerstone of the strategy to enhance Scotland's research capabilities and outcomes.

Investment in research infrastructure, expanded access to clinical trials, and robust collaboration across the Scottish life sciences ecosystem are all geared towards achieving better patient outcomes and fostering sustainable growth. The overarching goal is to strengthen the UK's position as a global leader in commercial clinical research, with Scotland playing a distinctive and important part in this national ambition. The combined efforts of a growing commercial research infrastructure and strong partnerships are instrumental in widening access to clinical trials, accelerating the adoption of new therapies, and ultimately reinforcing the entire UK life sciences ecosystem.

This development highlights new infrastructure and funding mechanisms (CRDCs, VPAG) designed to accelerate clinical research and medicines development in Scotland. Lawyers advising pharmaceutical, biotech, or academic clients should be aware of these new opportunities for engaging in clinical trials and the MHRA's emphasis on early regulatory engagement within this evolving Scottish life sciences ecosystem. It also signals potential compliance considerations for entities participating in these publicly-funded initiatives.

Source: Original reporting via GOV.UK